Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford University researchers are making important progress evaluating the impact of an important new programme to save the lives of children in Nepal, which is being discussed in Geneva this week.

Gavi – the Global Alliance for Vaccines and Immunization – is meeting in Geneva to discuss progress on its plans to vaccinate an additional 300 million children by 2020. The Oxford team are working on assessment of the introduction of new vaccines in one of the world’s poorest countries.

The latest work is built on ten years’ partnership between Oxford University's Oxford Vaccine Group, Kathmandu’s Patan Academy of Health Sciences and New Zealand’s Otago University. Together they have studied the spread and prevention of serious bacterial infections in Nepali children. Nepal is one of the world’s least economically developed countries in the world and infection-related illness imposes a high burden on its society and economy. Infections are particularly an issue for children less than five years of age, with pneumonia the leading cause of death for the age group.

Oxford’s Professor Andrew Pollard explained: ‘Vaccination is key to preventing fatal and serious infectious diseases in childhood – and throughout life. With limited resources, Nepal needs to make sure that any vaccines it introduces will be effective. We have worked with the Nepali doctors to assess a vaccine against Hib, an important cause of meningitis and pneumonia, and that vaccine is now part of Nepal’s expanded programme of immunisations.

‘We also looked at different ways to use a pneumonia vaccine that protects against ten types of pneumococcus, a common bacteria that can also cause pneumonia and meningitis. Our study with the team in Nepal showed that a programme of two doses of the vaccine in early life and one at nine months was a more effective way to prevent infections. The Nepalese Government adopted that programme last year.’

The team are now carrying out a four year evaluation to assess the impact of the pneumonia vaccine programme, funded by Gavi. This important follow-up impact study will look at the number of children hospitalised with meningitis and pneumonia as well as the number of children in Kathmandu carrying the pneumococcal bacteria.

Gavi aims to reach 300 million more children with vaccines between 2016 and 2020, preventing a further five to six million more deaths. 

Professor Andrew Pollard, Oxford Vaccine Group

The funding has also enabled the team to provide extra training to microbiology technicians at Patan hospital, enabling them to identify different strains of pneumococcus to improve monitoring of the bug and so strengthen efforts to limit its impact.

Professor Pollard said: ‘Gavi aims to reach 300 million more children with vaccines between 2016 and 2020, preventing a further five to six million more deaths. The information from Nepal regularly feeds into a global database, allowing researchers to spot emerging trends and perhaps identify weaknesses in the bacteria that we can target. The four-year study will also provide in-depth understanding of the effectiveness of vaccination in Nepal. That can provide lessons for vaccination efforts worldwide and ensure we meet the 300 million target.’

Similar stories

Alternating vaccines trial expands to include two additional vaccines

COVID-19 Clinical Trials Vaccinology

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

COVID-19 Vaccinology

Medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

COVID-19 Vaccinology

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

COVID-19 Vaccinology

- Oxford-AstraZeneca coronavirus vaccine 79% effective against symptomatic COVID-19 overall - Vaccine 100% effective against severe or critical symptomatic COVID-19 - No safety concerns reported

Professor Matthew Snape named NIHR Senior Investigator

Awards & Appointments Vaccinology

Four academics supported by the NIHR Oxford Biomedical Research Centre have been awarded a prestigious national award, among them Matthew Snape from the Oxford Vaccine Group.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

COVID-19 Research Vaccinology

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.